Live
- BJP urges EC to stop Cong’s ‘Guarantee Cards’ campaign aimed to 'induce voters'
- Congress cheated Madigas: Dr. RS Praveen Kumar
- CBDT signs record 125 pacts to ease tax payments by big multinational firms
- Kamal Nath accuses BJP of ‘threatening’ Congress leaders in Chhindwara
- Odisha: BJP, BJD allege violation of MCC
- PM Modi lands in Guwahati to kickstart poll campaign
- ‘100 day action plan’ is PM Modi’s signature style for setting goals and meeting targets
- BJP will change the Constitution if they come to power again, says Priyanka Gandhi
- BJP-led NDA to cross 390-mark in Lok Sabha polls, predicts India TV-CNX survey
- Haier launches new TV series in four sizes in India
Lupin shares fall 2.5 pc after USFDA observations on Goa plant
Shares of Lupin fell 2.5 per cent on Monday after the US health regulator made two observations following the inspection of its Goa plant and cautioned that the facility may be subject to regulatory action.
New Delhi: Shares of Lupin fell 2.5 per cent on Monday after the US health regulator made two observations following the inspection of its Goa plant and cautioned that the facility may be subject to regulatory action.
The scrip declined 2.49 per cent to close at Rs 743.95 on the BSE. During the day, it dropped 5.43 per cent to Rs 721.50. On the National Stock Exchange (NSE), shares fell 2.38 per cent to close at Rs 745.10 apiece. In terms of traded volume, 2.56 lakh shares were traded on the BSE and over 32 lakh shares on the NSE during the day.
The drug maker on Monday said the US health regulator made two observations after inspection of its Goa plant and cautioned that the facility may be subject to regulatory action and it may withhold approval of pending applications in which this facility is listed. The company has received a communication from the US Food and Drug Administration (USFDA), classifying the inspection conducted at its Goa facility between January 28 and February 8, 2019, as Official Action Indicated (OAI).
The inspection at the Goa facility had closed with two observations, Lupin said in a regulatory filing. "The USFDA has stated that this facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed," the company added.
The Mumbai-based drug maker, however, said it does not believe that the classification would have an impact on disruption of supplies or the existing revenues from operations of this facility. The company is in the process of sending further updates of its corrective actions to the USFDA and is hopeful of a positive outcome, it added.
